Alpha-cyclodextrin,
does it really help with Improvement of postprandial triglycerides, LDL, and body weight?
research showsOnly the acute postprandial-triglyceride signal is rated C. In a 401-person six-month RCT, LDL was -3.5 mg/dL (p=.13) and body weight was +0.64 kg (p=.15); both were nonsignificant, giving those subclaims a D character.
ads claimDescriptions may state that trapping dietary fat lowers TG, LDL, and body weight together. Long-term LDL and weight data are negative.
Useful facts when choosing a product
- The acute trial used 2 g per meal.
- The six-month trial required six tablets daily and had low adherence.
- Gas, bloating, or constipation may occur.
Chamgap Semantic Classification Code
Candidate index · review held
UNK.alpha-cyclodextrin.UNK.postprandial-triglycerides-ldl-and-body-weight.improve.placeboUnknown > Alpha-cyclodextrin > Unknown > postprandial triglycerides, LDL, and body weight > Improvement claim > Placebo
An automated migration candidate, not an issued permanent code; exact claim scope remains under review. This machine-generated migration candidate helps retrieval but is not a permanent assignment. The original verdict ID and URL remain authoritative.
What the research actually shows
Jarosz 2013 reported reduced postprandial TG iAUC after a single 2 g dose. Comerford 2011 reported 6.7% lower LDL and a 0.4 kg weight reduction among 28 adherent participants. In the Bessell 2020 six-month RCT of 401 participants, the placebo-adjusted differences were -3.5 mg/dL for LDL (p=.13) and +0.64 kg for body weight (p=.15), both nonsignificant.
Why this is classified as C (40)
The acute postprandial-triglyceride signal is C, while LDL and weight were negative in the 401-person longer RCT and are each rated D. Combining the separated subclaims supports an overall C with 40 points.
Counterpoint. A possible immediate TG response to a high-fat meal remains, but it is not equivalent to long-term LDL or weight effects.
Rejudgment record. New judgment — The acute postprandial-triglyceride signal is C, while LDL and weight were negative in the 401-person longer RCT and are each D; combining the subclaims supports C with 40 points.
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Postprandial triglycerides | C | One acute trial was positive, but data are limited. |
| LDL cholesterol | D | The 401-person six-month RCT was negative: -3.5 mg/dL, p=.13. |
| Body weight | D | The 401-person six-month RCT was negative: +0.64 kg, p=.15. |
Cross-check — AI research and Codex final gate
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Jarosz PA et al. 2013 | Double-blind crossover RCT | FBCx trademark research context | Three-hour postprandial TG | TG iAUC decreased; glucose and cholesterol did not change. | Supportive | |
| Bessell E et al. 2020 | Six-month double-blind 2×2 RCT | 401 | Products and funding from SFI Research | LDL and body weight | In intention-to-treat analysis, LDL was -3.5 mg/dL (p=.13) and body weight was +0.64 kg (p=.15), both nonsignificant. | Key |
| Comerford KB et al. 2011 | Two-month crossover trial | 28 | Product involvement | LDL and body weight | LDL fell 6.7% and weight 0.4 kg among adherent participants. | Supportive |
Receipt — 3 References
All 3 cited sources were verified for existence at the original page (as of 2026-07-11).
Final verification and publication gate: Codex · Evidence date: 2026-07-11 · Corrections: none
Cite this verdict
[Chamgap] Alpha-cyclodextrin x Improvement of postprandial triglycerides, LDL, and body weight — Evidence Grade C·40. 3 cited sources checked. Source: https://chamgap.com/en/verdicts/heart/alpha-cyclodextrin-triglycerides-ldl-weight/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.